Lurbinectedin and Tarlatamab in ES-SCLC

A panelist discusses how both lurbinectedin and tarlatamab remain important in the management of relapsed small cell lung cancer (SCLC). They note that while tarlatamab offers superior outcomes in recent studies, lurbinectedin continues to serve a vital role for patients ineligible for bispecific therapy or when access barriers exist.

A panelist discusses how clinical scenarios involving contraindications or resource limitations still justify lurbinectedin use, preserving treatment flexibility.

A panelist discusses how ongoing research, such as the IMforte trial, could expand lurbinectedin’s role into first-line maintenance, reshaping sequencing and therapeutic decision-making.